Who are Lu-177 PSMA-617's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): 177Lu-PSMA-I&T, 177Lu-PMSA-617, 177Lu-DOTATATE, 177Lu-TLX591, 177Lu-PSMA-617.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lu-177-psma-617.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Lu-177 PSMA-617 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lu-177 PSMA-617 (Lu-177 PSMA-617) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radioligand therapy. Area: Oncology.

phase 3 Radioligand therapy PSMA (prostate-specific membrane antigen) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Lu-177 PSMA-617 (Lu-177 PSMA-617) — Radboud University Medical Center. Lu-177 PSMA-617 is a radioligand that binds to prostate-specific membrane antigen (PSMA) on cancer cells and delivers targeted radiation to kill them.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Lu-177 PSMA-617 TARGET	Lu-177 PSMA-617	Radboud University Medical Center	phase 3	Radioligand therapy	PSMA (prostate-specific membrane antigen)
177Lu-PSMA-I&T	177Lu-PSMA-I&T	Weill Medical College of Cornell University	phase 3	Radioligand therapy	PSMA (prostate-specific membrane antigen)
177Lu-PMSA-617	177Lu-PMSA-617	UNICANCER	phase 3	Radioligand therapy	PSMA (prostate-specific membrane antigen)
177Lu-DOTATATE	177Lu-DOTATATE	Erasmus Medical Center	phase 3	Radioligand therapy	Somatostatin receptor 2 (SSTR2)
177Lu-TLX591	177Lu-TLX591	Telix Pharmaceuticals (Innovations) Pty Limited	phase 3	PSMA-targeted radioligand therapy	PSMA (prostate-specific membrane antigen)
177Lu-PSMA-617	177Lu-PSMA-617	European Organisation for Research and Treatment of Cancer - EORTC	phase 3	Radioligand therapy / Targeted radionuclide therapy	PSMA (Prostate-Specific Membrane Antigen)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Radioligand therapy class)

Erasmus Medical Center · 1 drug in this class
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · 1 drug in this class
Radboud University Medical Center · 1 drug in this class
Sinotau Pharmaceutical Group · 1 drug in this class
UNICANCER · 1 drug in this class
Weill Medical College of Cornell University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lu-177 PSMA-617 — Competitive Intelligence Brief. https://druglandscape.com/ci/lu-177-psma-617. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing